` 4887 (Sawai Group Holdings Co Ltd) vs Nikkei 225 Comparison - Alpha Spread

4887
vs
Nikkei 225

Over the past 12 months, has outperformed Nikkei 225, delivering a return of 4% compared to the Nikkei 225's 14% drop.

Stocks Performance
4887 vs Nikkei 225

Loading

Performance Gap
4887 vs Nikkei 225

Loading
4887
Nikkei 225
Difference

Performance By Year
4887 vs Nikkei 225

Loading
4887
Nikkei 225
Add Stock

Competitors Performance
Sawai Group Holdings Co Ltd vs Peers

Nikkei 225
4887
LLY
JNJ
NOVO B
ROG
Add Stock

Sawai Group Holdings Co Ltd
Glance View

Market Cap
254.7B JPY
Industry
Pharmaceuticals

Sawai Group Holdings Co., Ltd. stands as a prominent figure in the pharmaceutical landscape of Japan and beyond, rooted in a steadfast commitment to produce affordable generic medicines. Originating from humble beginnings in 1929, Sawai has evolved into a formidable player in the industry, underpinned by a strategy that blends innovation with an intricate understanding of healthcare needs. Known for its sharp focus on generic pharmaceutical products, the company has carved a niche by prioritizing the development and manufacture of high-quality, cost-efficient medications. This strategic orientation not only aligns with global healthcare trends but also meets the burgeoning demands of an aging population, both domestically and internationally. Central to Sawai's business model is their vertically integrated operation, covering everything from research and development to manufacturing and distribution. This comprehensive approach allows Sawai to maintain strict control over product quality while maximizing operational efficiency. Revenue flows from its diverse product portfolio, which includes a vast array of therapeutic areas such as cardiovascular, digestive, and central nervous system drugs. Moreover, Sawai's expansion into international markets, particularly in the United States through its subsidiary Upsher-Smith Laboratories, broadens its revenue base. By leveraging strategic acquisitions and partnerships, the company continues to fortify its presence on the global stage, all while steadfastly delivering on its promise of making healthcare accessible and affordable.

Intrinsic Value
3 127.01 JPY
Undervaluation 38%
Intrinsic Value
Price
Back to Top